This article describes Medicare beneficiaries' experience with the choice among Medicare drug discount cards and is based primarily on surveys and focus groups with beneficiaries as well as interviews with other stakeholders. Although competition and choice have the potential to reduce cost and enhance quality in the Medicare Program, our findings highlight some of the challenges involved in making choice work in practice. Despite the unique and temporary nature of the drug discount card program, these findings have considerable relevance to the Part D drug benefit and to other Medicare initiatives that rely on choice.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195003 | PMC |
J Am Acad Dermatol
January 2025
Harvard Medical School, Boston, MA; Department of Dermatology, Brigham and Women's Hospital, Boston, MA.
Pharmacoecon Open
January 2025
HTA & Pharmaceutical Economics Department, Italian Medicines Agency (AIFA), Rome, Italy.
Background: The authorization of new therapeutic indications for drugs already reimbursed by the Italian National Health Service (NHS) represents a matter of importance. This study aims to estimate the additional discount attributed to the extension of indications (EoIs) to explore the potential correlation between spending and negotiated discounts and to find specific factors (determinants) that impact on discount.
Methods: The study focused on drugs approved in Italy between 2003 and 2017 with at least four therapeutic indications, including the first approved and EoIs, with follow-up extended until 2021 to acquire all the information on the negotiation process that has been completed.
Pharmacoecon Open
January 2025
Department of Public Health Policy, School of Public Health, University of West Attica, 196 Alexandras Avenue, 115 21, Athens, Greece.
Background: Obesity is a global health issue with significant economic implications for health systems. Pharmacotherapy, including semaglutide 2.4 mg and liraglutide 3 mg, offers a treatment option for weight management; however, its cost-effectiveness requires evaluation.
View Article and Find Full Text PDFStat Med
February 2025
Division of Biostatistics, College of Public Health, The Ohio State University, Ohio, USA.
Leveraging external data information to supplement randomized clinical trials has been a popular topic in recent years, especially for medical device and drug discovery. In rare diseases, it is very challenging to recruit patients and run a large-scale randomized trial. To take advantage of real-world data from historical trials on the same disease, we can run a small hybrid trial and borrow historical controls to increase the power.
View Article and Find Full Text PDFSwiss Med Wkly
January 2025
Cancer Center und Research Center, Cantonal Hospital Graubünden, Chur, Switzerland.
Background And Objective: Because of the lack of effective targeted treatment options, docetaxel has long been the standard second-line therapy for patients with advanced non-small cell lung cancer, including the Kirsten rat sarcoma virus (KRAS) G12C mutation. The CodeBreak 200 trial demonstrated that sotorasib, a new drug targeting the G12C-mutated KRAS protein, modestly improved progression-free survival compared with docetaxel in patients whose cancer had progressed after receiving platinum chemotherapy and programmed cell death protein 1 (PD-1) / programmed death ligand 1 (PD-L1) inhibitors as first-line treatment. Consequently, sotorasib received temporary approval in Switzerland.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!